Showing results (181-190 of 201) with videos related to

Sort By:
Pageof 21
BMJ Open|October 9, 2024
Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 studyThomas D Norton, Mazhar Thakur, Samit Ganguly, et al.
Nature Communications|June 17, 2023
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administrationDean Follmann, Meagan P O'Brien, Jonathan Fintzi, et al.
Journal of the Pediatric Infectious Diseases Society|October 1, 2024
Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19Thomas D Norton, Mazhar Thakur, Samit Ganguly, et al.
Medrxiv : the Preprint Server for Health Sciences|July 3, 2026
Local and circulating cytotoxic CD4⁺ T cells are early markers of disease activity in pediatric Crohn's diseaseVeronika Niederlova, Kyle Kimler, Hengqi Betty Zheng, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 5, 2022
Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19Flonza Isa, Eduardo Forleo-Neto, Jonathan Meyer, et al.
Allergy|December 14, 2024
Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut AllergyR Sharon Chinthrajah, Sayantani B Sindher, Kari C Nadeau, et al.
JAMA Network Open|August 15, 2022
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical TrialCynthia Portal-Celhay, Eduardo Forleo-Neto, Will Eagan, et al.
Science Translational Medicine|October 29, 2025
The IL-33 and IL-4Rα blocking antibodies itepekimab and dupilumab modulate both distinct and common inflammatory mediators in asthmaSeblewongel Asrat, Wei Keat Lim, Subhashini Srivatsan, et al.
The New England Journal of Medicine|December 17, 2020
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19David M Weinreich, Sumathi Sivapalasingam, Thomas Norton, et al.
The Journal of Infectious Diseases|July 27, 2022
Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19Selin Somersan-Karakaya, Eleftherios Mylonakis, Vidya P Menon, et al.
Pageof 21